SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Trial Profile

SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs SL 401 (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Stemline Therapeutics
  • Most Recent Events

    • 06 Jul 2017 Planned number of patients changed from 60 to 120.
    • 06 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 06 Jul 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top